Development and evaluation of the hepaplate IPS: a high throughput organ on a chip IPS hepatotoxicty screening platform
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN271201600011C
- Awardee
-
Mimetas US Inc. UEI QGP7JLTGMAK9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $224,998
Award facts
- Opportunity
-
- PHS2016 Solicitation number
- Contract value 100% obligated
- $224,998.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 11 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Original award | $224,998 |
About this award
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Mimetas US Inc., a self-certified small disadvantaged business. The $224,998 Firm Fixed Price contract is for the "Development and Evaluation of the HepaPlate IPS: A High Throughput Organ on a Chip IPS Hepatotoxicity Screening Platform." The contract aims to develop and evaluate a high-throughput organ-on-a-chip platform for screening potential drug-induced liver toxicity using induced pluripotent stem (iPS) cell-derived hepatocytes. This is an SBIR Phase I award, which provides funding to small businesses to conduct research and development on innovative technologies with potential for commercialization. Mimetas US Inc. is a for-profit organization that specializes in advanced 3D cell culture and organ-on-a-chip technologies for disease modeling and drug discovery applications, with a focus on kidney diseases.
Quick answers
Who was awarded contract HHSN271201600011C?
HHSN271201600011C was awarded to Mimetas US Inc. by National Institute on Drug Abuse (National Institutes of Health) on May 12, 2016.
How much is contract HHSN271201600011C worth?
The government has obligated $224,998 on HHSN271201600011C.
Was contract HHSN271201600011C competed?
The extent of competition for HHSN271201600011C was full and open competition after exclusion of sources. The government received 11 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award